Rich Moscicki

Richard A. Moscicki, MD

Richard (Rich) A. Moscicki, MD, recently retired from his role as executive vice president of science and regulatory advocacy and the chief medical officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Dr. Moscicki joined PhRMA in 2017 after serving as the deputy center director for science operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) since 2013.  While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs. Previous positions include serving as chief medical officer at Genzyme Corporation from 1992 to 2011 where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company.  He served and a senior vice president and head of clinical development at Sanofi-Genzyme from 2011-2013.

Dr. Moscicki joined the Reagan-Udall Foundation for the FDA Board of Directors in 2023.